Recombinant anti-human-IL-1 beta Antilichaam (Canakinumab)

Target: IL-1 Beta Generic name: Canakinumab Product Origin: Recombinant in CHO cells Canakinumab is a recombinant, human anti-human-IL-1betamonoclonal antibody that belongs to the IgG1/kappa isotype subclass with a molecular mass of 145157 Daltons when deglycosylated. Canakinumab binds to human IL-1betaand neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra) . References: 1. Church LD, McDermott MF: Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009 Feb;11 (1) :81-89. 2. Lachmann HJ, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4;360 (23) :2416-25. doi:10.1056/NEJMoa0810787

Interleukin-1 beta, Catabolin

IL1B

3553

P01584

Human

Functional Assay, IP, ELISA, ICC/IF, IHC, FACS

Purity: >98.0% as determined by SEC-HPLC & SDS-PAGE.

Purified

10mM Phosphate pH-7.0, 150 mM NaCl, 20% Glycerol

Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

Specificity: Human IL1 beta. Does not cross react with other members of the interleukin-1 family. Inquire for more than 1 mg quantities. Availability 5-7 weeks.

PepMap Analysis of N terminal amino acids sequence : H chain: QVQLVESGGG, L chain: EIVLTQSPDFQS